Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Pidilizumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 13 Mar 2018 Status changed from active, no longer recruiting to discontinued as per sponsor decision to discontinue development of the study drug.
- 10 Jun 2017 Biomarkers information updated
- 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.